CN113966220A - 用靶向tlr-4的适体治疗tlr-4介导的疾病和病状 - Google Patents

用靶向tlr-4的适体治疗tlr-4介导的疾病和病状 Download PDF

Info

Publication number
CN113966220A
CN113966220A CN202080044106.5A CN202080044106A CN113966220A CN 113966220 A CN113966220 A CN 113966220A CN 202080044106 A CN202080044106 A CN 202080044106A CN 113966220 A CN113966220 A CN 113966220A
Authority
CN
China
Prior art keywords
aptamer
tlr
dose
aptoll
aspects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080044106.5A
Other languages
English (en)
Chinese (zh)
Inventor
大卫·塞加拉·德拉佩纳
利萨尔多·博斯卡·戈马尔
伊格纳西奥·利索安·赫尔南德斯
费尔南德·德卡斯特罗·苏布里埃
卡洛斯·萨拉戈萨
马卡雷纳·赫尔南德斯·希门尼斯
大卫·皮涅罗·德尔里奥
贝亚特里斯·费尔南德斯·戈麦斯
玛丽亚·安杰利斯·莫罗·桑切斯
迭戈·皮尔兹·罗德里格斯
玛丽亚·尤金尼亚·萨拉沃索·莱亚尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Healthcare Group
Merck Patent GmbH
Original Assignee
Aupu Tower Target Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aupu Tower Target Corp filed Critical Aupu Tower Target Corp
Publication of CN113966220A publication Critical patent/CN113966220A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202080044106.5A 2019-05-16 2020-05-16 用靶向tlr-4的适体治疗tlr-4介导的疾病和病状 Pending CN113966220A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962849068P 2019-05-16 2019-05-16
US201962849072P 2019-05-16 2019-05-16
US62/849,068 2019-05-16
US62/849,072 2019-05-16
EP19382425 2019-05-27
EP19382424 2019-05-27
EP19382425 2019-05-27
EP19382424 2019-05-27
PCT/IB2020/054655 WO2020230109A1 (en) 2019-05-16 2020-05-16 Treatment of tlr-4 mediated diseases and conditions with aptamers targeting tlr-4

Publications (1)

Publication Number Publication Date
CN113966220A true CN113966220A (zh) 2022-01-21

Family

ID=73288968

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080044106.5A Pending CN113966220A (zh) 2019-05-16 2020-05-16 用靶向tlr-4的适体治疗tlr-4介导的疾病和病状

Country Status (7)

Country Link
US (2) US20220233572A1 (https=)
EP (1) EP3969011A1 (https=)
JP (2) JP7789563B2 (https=)
CN (1) CN113966220A (https=)
AU (1) AU2020276703A1 (https=)
CA (2) CA3140285A1 (https=)
WO (2) WO2020230109A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12390172B2 (en) * 2021-02-19 2025-08-19 Canon Medical Systems Corporation Method and apparatus for displaying medical images
WO2024064288A1 (en) * 2022-09-22 2024-03-28 Thomas Jefferson University Tlr4 inhibitors for cancer treatment
IL321911A (en) 2023-01-05 2025-09-01 Merck Patent Gmbh Aptol molecules for the treatment of ischemic stroke and intracranial hemorrhages
AU2024275027A1 (en) 2023-05-22 2025-12-11 Merck Patent Gmbh New tlr-4 antagonist aptamers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPH088933B2 (ja) * 1987-07-10 1996-01-31 日本ゼオン株式会社 カテ−テル
SG10201406016SA (en) 2006-04-03 2014-11-27 Stella Aps Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
DK2149605T3 (da) 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
ES2599979T3 (es) 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
EP2619189B1 (en) 2010-09-24 2020-04-15 Zoetis Services LLC Isoxazoline oximes as antiparasitic agents
ES2555160B1 (es) 2014-06-24 2016-10-25 Aptus Biotech, S.L. Aptámeros específicos de TLR-4 y usos de los mismos
WO2020069313A2 (en) * 2018-09-28 2020-04-02 Henry Ford Health System Use of extracellular vesicles in combination with tissue plasminogen activator and/or thrombectomy to treat stroke

Also Published As

Publication number Publication date
JP7789563B2 (ja) 2025-12-22
JP2022533966A (ja) 2022-07-27
WO2020230108A1 (en) 2020-11-19
US20220233572A1 (en) 2022-07-28
CA3291318A1 (en) 2026-03-02
CA3140285A1 (en) 2020-11-19
JP2025148491A (ja) 2025-10-07
EP3969011A1 (en) 2022-03-23
US20220233570A1 (en) 2022-07-28
WO2020230109A1 (en) 2020-11-19
AU2020276703A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
JP7789563B2 (ja) Ｔｌｒ－４を標的とするアプタマーによるｔｌｒ－４媒介性の疾患および状態の治療
JP7398007B2 (ja) Ａｎｇｐｔｌ３発現を阻害する組成物及び方法
JP2023029942A (ja) トランスサイレチン（ｔｔｒ）媒介アミロイドーシスの治療方法
EP2569431B1 (en) Methods for identifying compounds which modulate interleukins 17 and 23 signaling activity
PT2596807E (pt) Aptâmeros de ligação ao complemento e agentes anti-c5 úteis no tratamento de distúrbios oculares
CN111542326B (zh) 转铁蛋白受体(TfR)的RNA适体
AU2023264015A1 (en) Lipid nanoparticle formulations for central nervous system delivery
US20240279667A1 (en) Compositions and methods of treating diseases associated with bile acid transporter
TW202405170A (zh) 用於抑制補體成分c3蛋白表達的組合物和方法
US20230304012A1 (en) Muscle regeneration and growth
US20220193114A1 (en) Neurogenesis
TW202540420A (zh) 用於抑制LPA的基因表現的siRNA，含其的組合物及其用途
KR20260030856A (ko) 보체 인자 b(cfb) 발현을 억제하기 위한 조성물 및 방법
US20170298128A1 (en) Methods and compositions for treating age-related disorders
TW202515584A (zh) 用於抑制微管相關蛋白ｔａｕ（ｍａｐｔ）表達的組合物和方法
KR20260012755A (ko) 응고 인자 xi(fxi) 발현을 억제하는 조성물 및 방법
WO2023167336A1 (ja) 線維化疾患の治療又は予防のための医薬組成物
US12540330B2 (en) Stem-loop compositions and methods for inhibiting vascular endothelial growth factor
JP2024529930A (ja) 低減されたオフターゲット効果を有する修飾低分子干渉ｒｎａ分子
WO2025252223A1 (zh) 一种抑制PCSK9基因表达的RNAi制剂及其应用
TW202532088A (zh) 抑制亨廷頓蛋白（htt）表達的組合物和方法
TW202521133A (zh) 抑制甲狀腺素運載蛋白(ttr)表達的組合物和方法
CN118922540A (zh) 前激肽释放酶调节组合物及其使用方法
CN119654413A (zh) Itfg1抑制性核酸
JP2025512445A (ja) Ｓｃａｐ活性を調節するための組成物及び方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20250801

Address after: Darmstadt

Applicant after: Merck Healthcare Group

Country or region after: Germany

Address before: Madrid

Applicant before: Aupu tower, Target Corp.

Country or region before: Spain

Effective date of registration: 20250804

Address after: Darmstadt

Applicant after: MERCK PATENT GmbH

Country or region after: Germany

Address before: Darmstadt

Applicant before: Merck Healthcare Group

Country or region before: Germany

TA01 Transfer of patent application right